Showing 1811-1820 of 4940 results for "".
- UCSF's HS PROGRESS Aims to Shed Light on Hidradenitis Suppurativahttps://practicaldermatology.com/news/ucsfs-hs-progress-aims-to-shed-light-on-hidradenitis-suppurativa/2462092/University of California-San Francisco (UCSF) is leading HS PROGRESS (Hidradenitis Suppurativa [HS] Prospective Observational Registry and bioSpecimen repoSitory), a multicenter, longitudinal study that aims to comprehensively characterize HS from clinical and biological perspectives. <
- Breaking News From Fall Clinical: Lebrikizumab Performs Well for Up to Two Years in ADhttps://practicaldermatology.com/news/ears-experienced-sustained-skin-clearance-itch-relief-and-reduced-disease-severity-with-monthly-maintenance-dosing-as-demonstrated-in-the-adjo/2462083/Patients with moderate-to-severe atopic dermatitis who continued treatment with investigational lebrikizumab for up to two years experienced sustained skin clearance, itch relief and reduced disease severity with monthly maintenance dosing, according to data from the ADjoin long-term extensi
- Potential Eczema Breakthrough: IL-31 Feedback Loop Causes the Urge to Itch and Cools Nearby Inflammationhttps://practicaldermatology.com/news/potential-eczema-breakthrough-il-31-feedback-loop-causes-the-urge-to-itch-and-cools-nearby-inflammation/2462077/In a breakthrough that could transform how doctors treat conditions from eczema to allergies, scientists at UC San Francisco (UCSF) have discovered a feedback loop centered on a single immune protein called IL-31 that causes the urge to itch and dials back nearby inflammation.
- Lebrikizumab Update: IL-13 Blocker Performs Well in AD Inadequately Controlled With Cyclosporinehttps://practicaldermatology.com/news/lebrikizumab-update-il-13-blocker-performs-well-in-ad-inadequately-controlled-with-cyclosporine/2462070/Lebrikizumab showed clinical improvements in combination with topical corticosteroids (TCS) in adult and adolescent patients with moderate-to-severe atopic dermatitis (AD) that was not adequately controlled with cyclosporine or for whom cyclosporine was not medically adv
- Tralokinumab Controls AD Over the Long Termhttps://practicaldermatology.com/news/adtralza-tralokinumab-controls-ad-over-the-long-term/2462069/Continuous use of Leo Pharma’s Adtralza (tralokinumab) provided long-term disease control in adult patients with moderate-to-severe atopic dermatitis (AD), according to a post hoc, interim, subgroup analysis of the ongoing ECZTEND study presented at the European Academy of Dermatology and V
- Drs. Jedd D. Wolchok and Lisa Newman Elected to National Academy of Medicinehttps://practicaldermatology.com/news/drs-jedd-d-wolchok-lisa-newman-elected-to-national-academy-of-medicine/2462055/Melanoma specialist Dr. Jedd D. Wolchok, the Meyer Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, in partnership with NewYork-Presbyterian, and Dr. Lisa Newman, chief of the section of breast surgery at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornel
- Professor Alexander Egeberg Named Head of Global Medical Affairs at Leo Pharmahttps://practicaldermatology.com/news/professor-alexander-egeberg-named-will-head-of-global-medical-affairs-at-leo-pharma/2462050/Professor Alexander Egeberg is LEO Pharma’s new Vice President, Head of Global Medical Affairs. The announcement was made ahead of the upcoming 32nd European Academy of Dermatology and Venereology (EADV) Congress. Alexander Egeberg joins LEO Pharma from his role as professor of de
- DecisionDx-Melanoma Outperforms MSKCC Nomogram in Predicting Sentinel Lymph Node Positivity in Melanomahttps://practicaldermatology.com/news/decisiondx-melanoma-outperforms-mskcc-nomogram-in-predicting-sentinel-lymph-node-positivity-in-melanoma/2462044/Castle Biosciences, Inc.’s DecisionDx-Melanoma outperformed a nomogram developed at the Memorial Sloan Kettering Cancer Center (MSKCC) in predicting the risk of sentinel lymph node (SLN) positivity in patients with cutaneous melanoma (CM), according to a new study in
- When Lightning Strikes: A Case Study of Staphylococcal Scalded Skin Syndrome in a 55-year-old Manhttps://practicaldermatology.com/news/when-lightning-strikes-a-case-study-of-staphylococcal-scalded-skin-syndrome-in-a-55-year-old-man/2462042/Five months after being struck by lightning, a 55-year-old male presented with a 2-day history of an erythematous rash. The patient noted his skin had been excessively dry since the lightning strike, and he recently added a new essential oil to his bath. His medical history includes liver failure
- AD Pipeline Update: FDA Rejects Lilly’s Lebrikizumab Due to Third-Party Manufacturing Issueshttps://practicaldermatology.com/news/ad-pipeline-update-fda-rejects-lillys-lebrikizumab-due-to-third-party-manufacturing-issues/2462037/The U.S. Food and Drug Administration (FDA) did not approve Eli Lilly's lebrikizumab biologic license application (BLA) for the treatment of moderate-to-severe atopic dermatitis due to findings during an inspection of a contract manufacturer. The letter cited findings